Targeted pharmacological 'reversal' of electrical remodelling by short-term antiarrhythmic drug treatment after cardioversion. The Flec-SL study within AFNET;Gezielte pharmakologische "umkehr" des elektrischen remodeling durch kurzzeit-antiarrhythmika-therapie? Die Flec-SL-studie im kompetenznetz vorhofflimmern

Medizinische Welt

Volumn 58, Issue 4, 2007, Pages 135-137

  Kirchhof, Paulus ^a   Andresen, D ^b   Meinertz, T ^c   Steinbeck, G ^d   Weiss, T ^a   Breithardt, G ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b VIVANTES KLINIKUM AM URBAN   (Germany)

^c UNIVERSITY HEART CENTER HAMBURG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antiarrhythmic drug treatment; Atrial fibrillation; Flec SL

Indexed keywords

FLECAINIDE;

ARTICLE; CARDIOVERSION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL;

EID: 34248995530     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230-246.
2. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367: 262-272.
3. Schotten U et al. Vorhofflimmern: Grundlagenforschung liefert neue Therapieansätze. Dtsch Ärztebl 2006; 103: A1743-A1748.
4. Fetsch T et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-1394.
5. Singh BN et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
6. Haverkamp W et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21: 1216-1231.
7. Kirchhof P et al. Targeted pharmacological reversal of electrical remodeling after cardioversion - rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005; 150: 899.
8. Kirchhof P et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003; 14: 1027-1033.
9. Fuster V et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 651-745.
10. Kirchhof P, Breithardt G. New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. Heart Rhythm 2007; in press.
11. Patten M et al. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 2006; 17: 1216-1220.